Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

From The Editors - TOP November 2017

TOP - November 2017, Vol 10, No 4 - From the Editors

 

In the November issue of The Oncology Pharmacist, we feature highlights of key presentations and studies from the 2017 American Society of Clinical Oncology annual meeting, which took place in Chicago, IL.

One presenter shared the results of the phase 3 OlympiAD clinical trial, which demonstrated significantly improved progression-free survival in women with HER2-negative metastatic breast cancer with a germline BRCA mutation who received the PARP inhibitor olaparib (Lynparza) versus standard chemotherapy. The data also showed a meaningful improvement in health-related quality-of-life measures in those who received olaparib.

“OlympiAD is the first phase 3 study in metastatic breast cancer demonstrating benefit for a PARP inhibitor over an active comparator. It is our opinion that olaparib could be an effective treatment option for women with BRCA mutations and metastatic HER2-negative breast cancer, including, importantly, women with BRCA mutations and triple-negative breast cancer,” Mark E. Robson, MD, Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York City, told attendees.

Results from another clinical trial, ALEX, were also presented at the meeting, and led to alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, being hailed as a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer.

“This is the first head-to-head trial to compare a next-generation ALK inhibitor with the standard of care, crizotinib. This global study establishes alectinib as the new standard of care for initial treatment in this setting. Alectinib was especially beneficial in controlling and preventing brain metastases, which can have a major impact on patients’ quality of life,” said Alice T. Shaw, MD, PhD, Director, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, Boston.

In another presentation by George W. Sledge, Jr, MD, Professor, Medical Oncology, Stanford University Medical Center, Palo Alto, CA, it was reported that adding the CDK4/CDK6 inhibitor abemaciclib to fulvestrant (Faslodex) extended progression-free survival by 7 months in women with hormone receptor–positive, HER2-negative advanced breast cancer.

“The response rate is, to the best of our knowledge, the highest recorded in an endocrine-resistant population,” Dr Sledge told listeners.

In addition, this issue provides valuable insight on the PD-1 inhibitor, pembrolizumab, which has achieved encouraging responses in patients with soft-tissue sarcoma; osimertinib, an EGFR inhibitor that extended progression-free survival compared with standard chemotherapy in patients with EGFR T790M mutation–positive lung cancer who had central nervous system metastases; dacomitinib as a likely new targeted therapy for patients with EGFR mutation–positive lung cancer; daratumumab, a monoclonal antibody being added to regimens for multiple myeloma; and the potential success of larotrectinib (LOXO-101), a novel drug that targets tropomyosin receptor kinase fusions and which has demonstrated excellent, consistent, and durable antitumor activity in a range of tumor types in adults and children.

We invite you to visit www.TheOncologyPharmacist.com to share your feedback about this issue with us, or send comments to info@TheOncologyPharmacist.com. We look forward to receiving your feedback.

Related Items
From The Editors: May 2022
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in From the Editors
From The Editors March 2022
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in From the Editors
From The Editors
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in From the Editors
From The Editors: November 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in From the Editors
From The Editors: October 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in From the Editors, Biosimilars
From The Editors September 2021
Patrick J. Medina, PharmD, BCOP
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in From the Editors
From The Editors July 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in From the Editors
From The Editors May 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in From the Editors
From The Editors March 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - March 2021 Vol 14, No 2 published on March 11, 2021 in From the Editors
From The Editors January 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in From the Editors
Last modified: July 22, 2021